Trial Profile

A Phase 1 Placebo-controlled Study of the Safety and Tolerability of Rectally Administered Single Ascending Doses of IW-3300 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IW-3300 (Primary)
Indications Bladder disorders; Endometriosis; Interstitial cystitis
Focus Adverse reactions
Sponsors Ironwood Pharmaceuticals

Most Recent Events

04 Aug 2022 Status changed from recruiting to completed, according to a Ironwood Pharmaceuticals media release.
25 Jan 2022 Status changed from not yet recruiting to recruiting.
04 Nov 2021 According to an Ironwood Pharmaceuticals media release, this trial is expected to start in the first quarter of 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com